Research into the mechanisms and risk factors underlying FA has elucidated some of the features of this disease and have suggested potential avenues for treatment, although much remains unknown.

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...